Home Alzheimer’s Disease FDA Approves Atezolizumab as a First-Line Treatment for Metastatic NSCLC Subgroup

FDA Approves Atezolizumab as a First-Line Treatment for Metastatic NSCLC Subgroup

The FDA approved atezolizumab (Tecentriq) as the first and only single-agent cancer immunotherapy with 3 dosing options, allowing administration every 2, 3, or 4 weeks, according to Genentech, the developer of the agent.

In particular, the agent is approved as a frontline monotherapy to treat adults with metastatic non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression (PD-L1 stained ≥ 50% of tumor cells [TC ≥ 50%] or PD-L1 stained tumor-infiltrating [IC] covering ≥ 10% of the tumor area [IC ≥ 10%]), as determined by an FDA approved test, with no EGFR or ALK genomic tumor aberrations.

“We are pleased to offer people with certain types of lung cancer a new chemotherapy-free option that can help prolong their lives and be administered on a flexible dosing schedule, including an option for once-a-month (atezolizumab) infusions,” Levi Garraway, MD, PhD,…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Reflections on Living With an Incurable Illness : braincancer

(I’ve checked with the moderators to make sure this is appropriate and a good fit for this subreddit. I'm a very private person, and...

This Foramen Magnum Meningioma almost killed me 18 years ago.

submitted by /u/dkrem Continue Reading to the Source

Patients, Family & Friends, and Healthcare professionals : braincancer

I am currently a PhD student based at the Marie Curie Palliative Care Research Centre at Cardiff University. My PhD is focussed on developing...

32 year old singer Tom Parker of The Wanted diagnosed with stage 4 glioblastoma

submitted by /u/Jexlan Continue Reading to the Source

Recent Comments